NASDAQ:IDIX Idenix Pharmaceuticals (IDIX) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free IDIX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Idenix Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Idenix Pharmaceuticals Stock (NASDAQ:IDIX)Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.Read More Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. IDIX Stock News HeadlinesMarch 20, 2024 | markets.businessinsider.comPositive Outlook for Citius Pharmaceuticals with Lymphir’s FDA Resubmission and Market PotentialMarch 18, 2024 | markets.businessinsider.comImprimis Pharmaceuticals earnings: here's what Wall Street expectsMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.January 22, 2024 | wsj.comNYSE Arca Pharmaceutical IndexJanuary 4, 2024 | markets.businessinsider.comRigel Pharma Collaborates With CONNECT To Conduct Phase 2 Trial Of Olutasidenib In GliomaNovember 27, 2023 | benzinga.comWhy Biodexa Pharmaceuticals Stock (BDRX) Is SkyrocketingOctober 11, 2023 | markets.businessinsider.comHold Rating on Inovio Pharmaceuticals: Potential Expedited Approval and Commercialization of INO-3107 for Recurrent Respiratory PapillomatosisSeptember 26, 2023 | benzinga.comNexus Pharmaceuticals Receives FDA Approval for Fluorescein Injection, USPMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.September 26, 2023 | msn.comWhy Intercept Pharmaceuticals Stock Is Skyrocketing TodaySeptember 11, 2023 | investing.comKOSDAQ Pharmaceuticals Technical AnalysisAugust 11, 2023 | msn.comChina drugmakers axe IPO plans as they face scrutiny in anti-graft driveJuly 20, 2023 | morningstar.comInDex Pharmaceuticals Holding ABJuly 16, 2023 | investing.comLegal & General Global Health & Pharmaceuticals Index Trust R Class Accumulation (0P00000C79)June 29, 2023 | markets.businessinsider.comEndo International Says Health Canada Approves XCOPRI To Treat EpilepsyJune 21, 2023 | benzinga.comBoard Member at Impel Pharmaceuticals Acquires Company Stock Options Worth 13,222 SharesJune 12, 2023 | cnn.comFirst-of-its-kind erectile dysfunction gel gets FDA’s OK for over-the-counter marketing, company saysJune 3, 2023 | reuters.comDrugmaker Mallinckrodt may file for bankruptcy again -WSJMay 28, 2023 | wsj.comS&P 500 Pharmaceuticals Biotechnology & Life Sciences Industry Group IndexMay 17, 2023 | thestreet.comMerck Adds HCV Candidates with Idenix BuyApril 7, 2023 | investing.comInDex Pharmaceuticals Holding AB (INDEX)April 6, 2023 | investing.comTOPIX Pharmaceutical Technical AnalysisMarch 22, 2023 | markets.businessinsider.comHere's what Wall Street expects from Imprimis Pharmaceuticals's earningsMarch 6, 2023 | insidermonkey.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call TranscriptFebruary 23, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Infinity Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with MEI PharmaFebruary 19, 2023 | wsj.comDow Jones U.S. Pharmaceuticals IndexJanuary 25, 2023 | marketwatch.comInovio Pharmaceuticals Inc. stock remains steady Wednesday, still outperforms marketSee More Headlines Receive IDIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idenix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:IDIX CUSIP45166R20 CIK1093649 Webwww.idenix.com Phone+1-617-9959800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report IDIX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Idenix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Idenix Pharmaceuticals investors own include Ariad Pharmaceuticals (ARIA), Arena Pharmaceuticals (ARNA), Dendreon (DNDNQ), Gilead Sciences (GILD), AbbVie (ABBV), Achillion Pharmaceuticals (ACHN), AEGR (AEGR), Aeterna Zentaris (AEZS), Amarin (AMRN) and BlackBerry (BB). This page (NASDAQ:IDIX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idenix Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.